These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27994475)

  • 1. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.
    Natesan SK; Chandrasekar PH
    Infect Drug Resist; 2016; 9():291-300. PubMed ID: 27994475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of isavuconazole in the treatment of invasive fungal infections.
    Wilson DT; Dimondi VP; Johnson SW; Jones TM; Drew RH
    Ther Clin Risk Manag; 2016; 12():1197-206. PubMed ID: 27536124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
    Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
    Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
    Rybak JM; Marx KR; Nishimoto AT; Rogers PD
    Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
    Ledoux MP; Denis J; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections.
    Donnelley MA; Zhu ES; Thompson GR
    Infect Drug Resist; 2016; 9():79-86. PubMed ID: 27330318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.
    Ellsworth M; Ostrosky-Zeichner L
    J Fungi (Basel); 2020 Nov; 6(4):. PubMed ID: 33260353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.
    Falci DR; Pasqualotto AC
    Infect Drug Resist; 2013 Oct; 6():163-74. PubMed ID: 24187505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
    Shirley M; Scott LJ
    Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles.
    Jørgensen R; Andersen SR; Astvad KMT; Arendrup MC
    mSphere; 2017; 2(3):. PubMed ID: 28497121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
    Riley TT; Muzny CA; Swiatlo E; Legendre DP
    Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis.
    Lewis RE; Wurster S; Beyda ND; Albert ND; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114861. PubMed ID: 31427139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
    Kohno S; Izumikawa K; Takazono T; Miyazaki T; Yoshida M; Kamei K; Ogawa K; Taniguchi S; Akashi K; Tateda K; Mukae H; Miyazaki Y; Okada F; Kanda Y; Kakeya H; Suzuki J; Kimura SI; Kishida M; Matsuda M; Niki Y
    J Infect Chemother; 2023 Feb; 29(2):163-170. PubMed ID: 36307059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Perspectives on Antimicrobial Agents: Isavuconazole.
    Lewis JS; Wiederhold NP; Hakki M; Thompson GR
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0017722. PubMed ID: 35969068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.